Population variability in biological adaptive responses to DNA damage and the shapes of carcinogen dose-response curves
- PMID: 15996697
- DOI: 10.1016/j.taap.2005.04.027
Population variability in biological adaptive responses to DNA damage and the shapes of carcinogen dose-response curves
Abstract
Carcinogen dose-response curves for both ionizing radiation and chemicals are typically assumed to be linear at environmentally relevant doses. This assumption is used to ensure protection of the public health in the absence of relevant dose-response data. A theoretical justification for the assumption has been provided by the argument that low dose linearity is expected when an exogenous agent adds to an ongoing endogenous process. Here, we use computational modeling to evaluate (1) how two biological adaptive processes, induction of DNA repair and cell cycle checkpoint control, may affect the shapes of dose-response curves for DNA-damaging carcinogens and (2) how the resulting dose-response behaviors may vary within a population. Each model incorporating an adaptive process was capable of generating not only monotonic dose-responses but also nonmonotonic (J-shaped) and threshold responses. Monte Carlo analysis suggested that all these dose-response behaviors could coexist within a population, as the spectrum of qualitative differences arose from quantitative changes in parameter values. While this analysis is largely theoretical, it suggests that (a) accurate prediction of the qualitative form of the dose-response requires a quantitative understanding of the mechanism, (b) significant uncertainty is associated with human health risk prediction in the absence of such quantitative understanding and (c) a stronger experimental and regulatory focus on biological mechanisms and interindividual variability would allow flexibility in regulatory treatment of environmental carcinogens without compromising human health.
Similar articles
-
Arsenic, mode of action at biologically plausible low doses: what are the implications for low dose cancer risk?Toxicol Appl Pharmacol. 2005 Sep 1;207(2 Suppl):557-64. doi: 10.1016/j.taap.2005.01.048. Toxicol Appl Pharmacol. 2005. PMID: 15996700 Review.
-
Low doses and thresholds in genotoxicity: from theories to experiments.J Exp Clin Cancer Res. 2001 Sep;20(3):315-25. J Exp Clin Cancer Res. 2001. PMID: 11718209 Review.
-
The road to linearity: why linearity at low doses became the basis for carcinogen risk assessment.Arch Toxicol. 2009 Mar;83(3):203-25. doi: 10.1007/s00204-009-0412-4. Epub 2009 Feb 27. Arch Toxicol. 2009. PMID: 19247635 Review.
-
A comprehensive approach for integration of toxicity and cancer risk assessments.Regul Toxicol Pharmacol. 1999 Feb;29(1):23-36. doi: 10.1006/rtph.1998.1273. Regul Toxicol Pharmacol. 1999. PMID: 10051416 Review.
-
Analysis of in vivo mutation data can inform cancer risk assessment.Regul Toxicol Pharmacol. 2008 Jul;51(2):151-61. doi: 10.1016/j.yrtph.2008.01.015. Epub 2008 Feb 1. Regul Toxicol Pharmacol. 2008. PMID: 18321622
Cited by
-
Risk Analysis Implications of Dose-Response Thresholds for NLRP3 Inflammasome-Mediated Diseases: Respirable Crystalline Silica and Lung Cancer as an Example.Dose Response. 2019 Apr 2;17(2):1559325819836900. doi: 10.1177/1559325819836900. eCollection 2019 Apr-Jun. Dose Response. 2019. PMID: 31168301 Free PMC article.
-
Modeling Dose-response at Low Dose: A Systems Biology Approach for Ionization Radiation.Dose Response. 2010 Mar 18;8(4):456-77. doi: 10.2203/dose-response.09-054.Zhao. Dose Response. 2010. PMID: 21191485 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
